Buchumschlag

Advances in cell therapy: progress and challenges in hematological and solid tumors

Cell-based therapies harness the endogenous ability of the immune system to fight cancer and have shown promising results in the treatment of hematological malignancies. However, their clinical application beyond B cell malignancies is hampered by numerous hurdles, ranging from relapsed disease to a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: D'Avanzo, Claudia (VerfasserIn) , Blaeschke, Franziska (VerfasserIn) , Lysandrou, Memnon (VerfasserIn) , Ingelfinger, Florian (VerfasserIn) , Zeiser, Robert (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2024
In: Trends in pharmacological sciences
Year: 2024, Jahrgang: 45, Heft: 12, Pages: 1119-1134
ISSN:1873-3735
DOI:10.1016/j.tips.2024.10.016
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.tips.2024.10.016
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0165614724002268
Volltext
Verfasserangaben:Claudia D’Avanzo, Franziska Blaeschke, Memnon Lysandrou, Florian Ingelfinger, and Robert Zeiser
Beschreibung
Zusammenfassung:Cell-based therapies harness the endogenous ability of the immune system to fight cancer and have shown promising results in the treatment of hematological malignancies. However, their clinical application beyond B cell malignancies is hampered by numerous hurdles, ranging from relapsed disease to a hostile tumor microenvironment (TME). Recent advances in cell engineering and TME modulation may expand the applicability of these therapies to a wider range of cancers, creating new treatment possibilities. Breakthroughs in advanced gene editing and sophisticated cell engineering, have also provided promising solutions to longstanding challenges. In this review, we examine the challenges and future directions of the most prominent cell-based therapies, including chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes (TILs), and natural killer (NK) cells, and emerging modalities. We provide a comprehensive analysis of emerging cell types and combination strategies translated into clinical trials, offering insights into the next generation of cell-based cancer treatments
Beschreibung:Online verfügbar: 27. November 2024, Artikelversion: 5. Dezember 2024
Gesehen am 05.05.2025
Beschreibung:Online Resource
ISSN:1873-3735
DOI:10.1016/j.tips.2024.10.016

Ähnliche Einträge